Alterity Therapeutics Stock Beta
| ATHE Stock | USD 2.04 0.06 2.86% |
Alterity Therapeutics fundamentals help investors to digest information that contributes to Alterity Therapeutics' financial success or failures. It also enables traders to predict the movement of Alterity Stock. The fundamental analysis module provides a way to measure Alterity Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterity Therapeutics stock.
Alterity | Beta |
Alterity Therapeutics Company Beta Analysis
Alterity Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Alterity Therapeutics Beta | 0.72 |
Most of Alterity Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterity Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alterity Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Alterity Therapeutics is extremely important. It helps to project a fair market value of Alterity Stock properly, considering its historical fundamentals such as Beta. Since Alterity Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alterity Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alterity Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Alterity Therapeutics has a Beta of 0.716. This is 16.74% lower than that of the Biotechnology sector and 48.49% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Alterity Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in beta category among related companies.
Alterity Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Alterity Therapeutics from analyzing Alterity Therapeutics' financial statements. These drivers represent accounts that assess Alterity Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Alterity Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 13.1M | 17.7M | 14.7B | 10.2B | 9.2B | 9.7B | |
| Enterprise Value | (1.3M) | 8.6M | 14.6B | 10.2B | 9.2B | 9.7B |
Alterity Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alterity Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alterity Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Alterity Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Alterity Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alterity Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alterity Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 55.1 K | Bank Of Montreal | 2023-12-31 | 14.9 K | Bmo Capital Markets Corp. | 2023-12-31 | 14.9 K | Virtu Financial Llc | 2023-12-31 | 10.8 K | Twin Lakes Capital Management, Llc | 2023-12-31 | 5.9 K | Providence Capital Advisors, Llc | 2023-12-31 | 200 | Advisor Group Holdings, Inc. | 2023-12-31 | 81.0 | Sugarloaf Wealth Management, Llc | 2023-12-31 | 33.0 | Steward Partners Investment Advisory, Llc | 2023-12-31 | 6.0 | Coppell Advisory Solutions Llc | 2023-12-31 | 5.0 | Ubs Group Ag | 2023-12-31 | 0.0 |
As returns on the market increase, Alterity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alterity Therapeutics is expected to be smaller as well.
Alterity Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (3.48) % | ||||
| Current Valuation | 5.87 B | ||||
| Shares Outstanding | 8.73 M | ||||
| Shares Owned By Institutions | 1.02 % | ||||
| Number Of Shares Shorted | 85.89 K | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 1.73 X | ||||
| Price To Sales | 7.48 X | ||||
| Revenue | 2.61 M | ||||
| Gross Profit | 3.63 M | ||||
| EBITDA | (15.19 M) | ||||
| Net Income | (13.81 M) | ||||
| Cash And Equivalents | 34.81 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 210.38 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.07 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (20.07 M) | ||||
| Short Ratio | 0.49 X | ||||
| Earnings Per Share | (1.95) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 18.33 M | ||||
| Total Asset | 27.32 M | ||||
| Retained Earnings | (195.13 M) | ||||
| Working Capital | 22.67 M | ||||
| Current Asset | 14.26 M | ||||
| Current Liabilities | 1.73 M | ||||
| Net Asset | 27.32 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alterity Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alterity Therapeutics' short interest history, or implied volatility extrapolated from Alterity Therapeutics options trading.
Pair Trading with Alterity Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alterity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alterity Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Alterity Stock
| 0.57 | TIL | Instil Bio | PairCorr |
| 0.54 | OGI | OrganiGram Holdings Fiscal Year End 17th of December 2024 | PairCorr |
| 0.52 | LLY | Eli Lilly | PairCorr |
| 0.51 | GANX | Gain Therapeutics | PairCorr |
| 0.46 | HLN | Haleon plc | PairCorr |
The ability to find closely correlated positions to Alterity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alterity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alterity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alterity Therapeutics to buy it.
The correlation of Alterity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alterity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alterity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alterity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alterity Therapeutics Piotroski F Score and Alterity Therapeutics Altman Z Score analysis. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.Note that the Alterity Therapeutics information on this page should be used as a complementary analysis to other Alterity Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Alterity Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.6 | Quarterly Revenue Growth (0.20) | Return On Assets (0.29) | Return On Equity (0.54) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.